Latest On Armata Pharmaceuticals Inc (ARMP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 06:30 EST | News | Armata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79M | N/A |  |
| 2023-03-17 05:49 EST | News | Armata Pharmaceuticals GAAP EPS of -$0.29 misses by $0.01, revenue of $1.05M misses by $0.62M | N/A | |
| 2023-03-06 11:05 EST | News | Armata surges 15% as inhaled bacterial infection drug shows promise in lung disorder patients | N/A | |
| 2022-11-09 20:41 EST | News | Armata Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $1.34M misses by $0.32M | N/A | |
| 2022-08-11 23:11 EST | News | Armata Pharmaceuticals GAAP EPS of -$0.26, revenue of $1.88M | N/A | |
About Armata Pharmaceuticals Inc (ARMP):
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.
General
- Name Armata Pharmaceuticals Inc
- Symbol ARMP
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 33
- Last Split Factor1:14
- Last Split Date2019-05-10
- Fiscal Year EndDecember
- IPO Date2011-03-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.armatapharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 245.15
- Price/Book (Most Recent Quarter) 4.61
- Enterprise Value Revenue 347.03
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$0.85
- Next Year EPS Estimate -$0.61
- Next Quarter EPS Estimate -$0.19
- Operating Margin -5908%
- Return on Assets -31%
- Return on Equity -94%
- Revenue 319000
- Earnings Per Share -$0.14
- Revenue Per Share $0.02
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 112.52 million
- EBITDA -11489000
- Analyst Target Price $7.25
- Book Value Per Share $1.32
Share Statistics
- Shares Outstanding 20.61 million
- Shares Float 8.38 million
- % Held by Insiders 6312%
- % Held by Institutions 15.98%
- Shares Short 58547
- Shares Short Prior Month 99571
- Short Ratio 0.6
- Short % of Float 1%
Technicals
- 52 Week High $6.39
- 52 Week Low $2.56
- 50 Day Moving Average 5.62
- 200 Day Moving Average 3.82
Dividends
- Dividend Date 2019-05-10
- ExDividend Date N/A
- Dividend Yield 0%
Armata Pharmaceuticals Inc (ARMP) Dividend Calendar:
ARMP's last dividend payment was made to shareholders on May 10, 2019.
Armata Pharmaceuticals Inc (ARMP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Armata Pharmaceuticals Inc (ARMP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Armata Pharmaceuticals Inc (ARMP) Chart:
Armata Pharmaceuticals Inc (ARMP) News:
Below you will find a list of latest news for Armata Pharmaceuticals Inc (ARMP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Armata Pharmaceuticals Inc (ARMP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ARMP Trades:
Armata Pharmaceuticals Inc (ARMP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-22 | DEF 14A (Other definitive proxy statements) | |
| 2020-10-22 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-18 | 8-K (Current report) | |
| 2020-06-18 | 8-K (Current report) | |
| 2020-05-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-04-28 | 8-K (Current report) | |
| 2020-04-09 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-04-09 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-04-08 | EFFECT (Notice of Effectiveness) | |
| 2020-04-08 | EFFECT (Notice of Effectiveness) | |
| 2020-04-07 | UPLOAD (SEC-generated letter) | |
| 2020-04-07 | UPLOAD (SEC-generated letter) | |
| 2020-04-06 | CORRESP (Correspondence) | |
| 2020-04-06 | CORRESP (Correspondence) | |
| 2020-04-01 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-04-01 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-03-31 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-03-31 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-03-30 | 8-K (Current report) | |
Armata Pharmaceuticals Inc (ARMP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Armata Pharmaceuticals Inc (ARMP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 6312%
Institutional Ownership: 1598%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-03-27 | Innoviva, Inc. | 10% Share Holder | Buy | 7,717,661.00 | 2.87 | 22,149,687.07 | 8,710,800.00 | |